JP2023549533A - 眼の状態を処置するための薬理剤 - Google Patents
眼の状態を処置するための薬理剤 Download PDFInfo
- Publication number
- JP2023549533A JP2023549533A JP2023528761A JP2023528761A JP2023549533A JP 2023549533 A JP2023549533 A JP 2023549533A JP 2023528761 A JP2023528761 A JP 2023528761A JP 2023528761 A JP2023528761 A JP 2023528761A JP 2023549533 A JP2023549533 A JP 2023549533A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- halo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113691P | 2020-11-13 | 2020-11-13 | |
| US63/113,691 | 2020-11-13 | ||
| US202163215818P | 2021-06-28 | 2021-06-28 | |
| US63/215,818 | 2021-06-28 | ||
| PCT/US2021/072405 WO2022104383A1 (en) | 2020-11-13 | 2021-11-15 | Pharmacological agents for treating conditions of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549533A true JP2023549533A (ja) | 2023-11-27 |
| JP2023549533A5 JP2023549533A5 (enExample) | 2024-11-25 |
Family
ID=81601792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528761A Pending JP2023549533A (ja) | 2020-11-13 | 2021-11-15 | 眼の状態を処置するための薬理剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240000812A1 (enExample) |
| EP (1) | EP4243798A4 (enExample) |
| JP (1) | JP2023549533A (enExample) |
| CA (1) | CA3202073A1 (enExample) |
| MX (1) | MX2023005675A (enExample) |
| WO (1) | WO2022104383A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872236B2 (en) | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| WO2025090994A1 (en) * | 2023-10-26 | 2025-05-01 | Plex Pharmaceuticals, Inc. | Compositions for treating cataracts and/or presbyopia eye diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095257A2 (en) * | 2013-12-18 | 2015-06-25 | Emory University | Managing visual dysfunction or loss of vision for diabetic subjects |
| WO2019195761A2 (en) * | 2018-04-05 | 2019-10-10 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| JP2024524433A (ja) * | 2021-06-28 | 2024-07-05 | プレックス ファーマスーティカルズ,インク | 白内障および老眼眼疾患を予防および治療するための薬理学的薬剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE439863T1 (de) * | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダSom Innovation Biotech, S.L. | トランスサイレチン関連アミロイドーシスの新規療法 |
| WO2013098416A2 (fr) * | 2011-12-30 | 2013-07-04 | Ecole Nationale Superieure De Chimie De Clermont Ferrand | Composes anti-douleur |
| WO2014164667A1 (en) * | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| EP3683618A1 (en) * | 2019-01-21 | 2020-07-22 | Essilor International (Compagnie Generale D'optique) | System and method for demonstrating an optical disorder |
| JP2024520837A (ja) * | 2021-06-08 | 2024-05-24 | プレックビジョン、バイオテクノロジーズ、リミテッド | ダニの抑制又は滅殺及び眼球乾燥症の治療におけるcyp450阻害剤の使用 |
-
2021
- 2021-11-15 WO PCT/US2021/072405 patent/WO2022104383A1/en not_active Ceased
- 2021-11-15 US US18/037,021 patent/US20240000812A1/en active Pending
- 2021-11-15 CA CA3202073A patent/CA3202073A1/en active Pending
- 2021-11-15 EP EP21893092.3A patent/EP4243798A4/en active Pending
- 2021-11-15 JP JP2023528761A patent/JP2023549533A/ja active Pending
- 2021-11-15 MX MX2023005675A patent/MX2023005675A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095257A2 (en) * | 2013-12-18 | 2015-06-25 | Emory University | Managing visual dysfunction or loss of vision for diabetic subjects |
| WO2019195761A2 (en) * | 2018-04-05 | 2019-10-10 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| JP2024524433A (ja) * | 2021-06-28 | 2024-07-05 | プレックス ファーマスーティカルズ,インク | 白内障および老眼眼疾患を予防および治療するための薬理学的薬剤 |
Non-Patent Citations (1)
| Title |
|---|
| AMYLOID, vol. 28, JPN6025049977, 2021, pages 24 - 29, ISSN: 0005865493 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023005675A (es) | 2023-07-31 |
| EP4243798A1 (en) | 2023-09-20 |
| WO2022104383A1 (en) | 2022-05-19 |
| CA3202073A1 (en) | 2022-05-19 |
| US20240000812A1 (en) | 2024-01-04 |
| EP4243798A4 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230293527A1 (en) | Treatment of inflammatory disorders | |
| US20240000812A1 (en) | Pharmacological agents for treating conditions of the eye | |
| ES2374336T3 (es) | Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo. | |
| US11872236B2 (en) | Pharmacological agents for treating ocular diseases | |
| KR20180095928A (ko) | 노안의 치료를 위한 조성물 | |
| WO2023202705A1 (zh) | 一种眼用制剂及其在治疗老花眼中的应用 | |
| RU2733432C1 (ru) | Лечение вирусного конъюнктивита с применением ранпирназы и/или амфиназы | |
| CN116963727A (zh) | 用于治疗眼部病症的药剂 | |
| JPWO2020129965A1 (ja) | 4−フェニル酪酸を含有する老視の治療または予防剤 | |
| EP3976017A1 (en) | Pharmacological agents for treating protein aggregation diseases of the eye | |
| CA2744898A1 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| JP6499290B2 (ja) | メラニンならびにメラニン類似体、前駆体、および誘導体による眼疾患、眼障害および眼症状の治療および予防のための方法 | |
| CN110650740A (zh) | 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物 | |
| JP2011518828A (ja) | 眼球障害の処置のためのpai−1の発現および活性インヒビター | |
| HK40103320A (en) | Pharmacological agents for treating conditions of the eye | |
| WO2022034909A1 (ja) | セペタプロストを含有する医薬製剤 | |
| US20250019352A1 (en) | Pharmacological agents for treating ophthalmic diseases | |
| JP2000507205A (ja) | 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用 | |
| TW200904429A (en) | Compositions and methods for modulating inflammation using fluoroquinolones | |
| ES2272771T3 (es) | Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento. | |
| TW201318628A (zh) | 含有黃素腺嘌呤二核苷酸或其塩為有效成分之角膜上皮細胞死亡抑制劑 | |
| JP2010013387A (ja) | 血管新生阻害剤 | |
| HK40050888A (en) | Pharmacological agents for treating ocular diseases | |
| TW200536517A (en) | Compositions of a phenyl acetic acid cyclooxygenase-2 selective inhibitor for the treatment of cyclooxygenase-2 mediated ocular disorders | |
| JP2002201129A (ja) | 外眼部炎症疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260521 |